Anticoagulation for Atrial Fibrillation in Heart Failure Patients: Balancing Between Scylla and Charybdis

Overview

Journal J Geriatr Cardiol

Specialty Geriatrics

Date 2021 Jun 21

PMID 34149824

Citations 8

Authors

Grigorios Tsigkas

Anastasios Apostolos

Stefanos Despotopoulos

Georgios Vasilagkos

Angeliki Papageorgiou

Eleftherios Kallergis

Georgios Leventopoulos

Virginia Mplani

Ioanna Koniari

Dimitrios Velissaris

John Parissis

Affiliations

Soon will be listed here.

Abstract

The management of heart failure (HF) and atrial fibrillation (AF) in real-world practice remains a debating issue, while the number of HF patients with AF increase dramatically. While it is unclear if rhythm or rate control therapy is more beneficial and under which circumstances, anticoagulation therapy is the cornerstone of the AF-HF patients' approach. Vitamin-K antagonists were the gold-standard during the past, but currently their usage is limited in specific conditions. Non-vitamin K oral anticoagulants (NOACs) have gained ground during the last ten years and considered as gold-standard of a wide spectrum of HF phenotypes. The current manuscript aims to review the current literature regarding the indications and the optimal choice and usage of NOACs in HF patients with AF.

Citing Articles

Imaging of Left Main Coronary Artery; Untangling the Gordian Knot.

Apostolos A, Gerakaris A, Tsoni E, Pappelis K, Vasilagkos G, Bousoula E Rev Cardiovasc Med. 2024; 24(1):26.

PMID: 39076882 PMC: 11270402. DOI: 10.31083/j.rcm2401026.

Exploring the link between blood pressure variability and atrial fibrillation: current insights and future directions.

Konstantinou K, Apostolos A, Tsiachris D, Dimitriadis K, Papakonstantinou P, Pappelis K J Hum Hypertens. 2024; 38(8):583-594.

PMID: 39026101 DOI: 10.1038/s41371-024-00936-z.

Unraveling the Paradox: Can Anticoagulation Improve Outcomes in Patients With Heart Failure and Increased Bleeding Risk?.

Saeed D, Fuenmayor D, Nino Medina J, Saleh I, Castiblanco Torres J, Horn W Cureus. 2024; 16(4):e57544.

PMID: 38707016 PMC: 11068119. DOI: 10.7759/cureus.57544.

The Application of Precision Medicine in Structural Heart Diseases: A Step towards the Future.

Chrysostomidis G, Apostolos A, Papanikolaou A, Konstantinou K, Tsigkas G, Koliopoulou A J Pers Med. 2024; 14(4).

PMID: 38673001 PMC: 11051532. DOI: 10.3390/jpm14040375.

A review of the impact, pathophysiology, and management of atrial fibrillation in patients with heart failure with preserved ejection fraction.

Dye C, Dela Cruz M, Larsen T, Nair G, Marinescu K, Suboc T Am Heart J Plus. 2024; 33:100309.

PMID: 38510554 PMC: 10946048. DOI: 10.1016/j.ahjo.2023.100309.

References

von Lueder T, Atar D, Agewall S, Jensen J, Hopper I, Kotecha D . All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. Am J Ther. 2019; 26(6):e671-e678. DOI: 10.1097/MJT.0000000000000883. View

Ripley T, Harrison D, Germany R, Adamson P . Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study. Clin Ther. 2010; 32(3):506-14. DOI: 10.1016/j.clinthera.2010.03.001. View

Jochheim D, Barbanti M, Capretti G, Stefanini G, Hapfelmeier A, Zadrozny M . Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2019; 12(16):1566-1576. DOI: 10.1016/j.jcin.2019.03.003. View

Ferreira J, Ezekowitz M, Connolly S, Brueckmann M, Fraessdorf M, Reilly P . Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail. 2013; 15(9):1053-61. DOI: 10.1093/eurjhf/hft111. View

van der Wal H, van Deursen V, van der Meer P, Voors A . Comorbidities in Heart Failure. Handb Exp Pharmacol. 2017; 243:35-66. DOI: 10.1007/164_2017_27. View

Kim E, Ozonoff A, Hylek E, Berlowitz D, Ash A, Miller D . Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thromb Haemost. 2015; 114(1):70-7. DOI: 10.1160/TH14-09-0754. View

Friberg L, Oldgren J . Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart. 2017; 4(2):e000682. PMC: 5623334. DOI: 10.1136/openhrt-2017-000682. View

McMurray J, Ezekowitz J, Lewis B, Gersh B, van Diepen S, Amerena J . Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013; 6(3):451-60. DOI: 10.1161/CIRCHEARTFAILURE.112.000143. View

Savarese G, Giugliano R, Rosano G, McMurray J, Magnani G, Filippatos G . Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC Heart Fail. 2016; 4(11):870-880. DOI: 10.1016/j.jchf.2016.07.012. View

10.

Lerakis S, Synetos A, Toutouzas K, Stefanadis C . Transcatheter occlusion devices for the prevention of stroke in patients with atrial fibrillation. Hellenic J Cardiol. 2008; 49(1):33-6. View

11.

Olsson L, Swedberg K, Ducharme A, Granger C, Michelson E, McMurray J . Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006; 47(10):1997-2004. DOI: 10.1016/j.jacc.2006.01.060. View

12.

Guo W, Chen X, Tian X, Li L . Differences In Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis. Clin Epidemiol. 2019; 11:911-921. PMC: 6778450. DOI: 10.2147/CLEP.S219335. View

13.

Laliberte F, Cloutier M, Nelson W, Coleman C, Pilon D, Olson W . Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014; 30(7):1317-25. DOI: 10.1185/03007995.2014.907140. View

14.

Holmes M, Hunt B, Shearer M . The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev. 2011; 26(1):1-14. DOI: 10.1016/j.blre.2011.07.002. View

15.

Steinberg B, Zhao X, Heidenreich P, Peterson E, Bhatt D, Cannon C . Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012; 126(1):65-75. DOI: 10.1161/CIRCULATIONAHA.111.080770. View

16.

Huang W, Singer D, Wu Y, Chiang C, Weng H, Lee M . Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis. JAMA Neurol. 2018; 75(12):1511-1518. PMC: 6583193. DOI: 10.1001/jamaneurol.2018.2215. View

17.

Sobue Y, Watanabe E, Lip G, Koshikawa M, Ichikawa T, Kawai M . Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart Vessels. 2017; 33(4):403-412. DOI: 10.1007/s00380-017-1073-5. View

18.

Brown L, Boos C . Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. Int J Cardiol. 2016; 227:863-868. DOI: 10.1016/j.ijcard.2016.09.086. View

19.

Hart R, Pearce L, Aguilar M . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-67. DOI: 10.7326/0003-4819-146-12-200706190-00007. View

20.

Koniari I, Kounis N, Tsigkas G, Hahalis G . Device-associated thrombus formation after left atrial appendage occlusion. Catheter Cardiovasc Interv. 2017; 92(3):E215. DOI: 10.1002/ccd.27152. View